Update on the physiology and pathology of factor IX activation by factor XIa.
Factor IX is a key component of the plasma system that forms a fibrin clot at a site of vascular injury. Activation of factor IX by factor XIa is required in certain situations to prevent bleeding from premature clot degradation. Factor XIa is a coagulation protease comprised of two identical subunits. The biochemical and physiologic implications of this unusual structural feature are being actively investigated. Congenital factor XI deficiency causes a mild-to-moderate bleeding disorder, with hemorrhage typically involving the oral/nasal cavities and the urinary tract. Current treatment recommendations take this tissue-specific bleeding pattern into account and target factor replacement to certain types of procedures and clinical situations. Results from animal models and human population studies indicate that factor XI contributes to thromboembolic disease. This protease may therefore be a legitimate therapeutic target.
Smith
Stephen B
SB
Department of Pathology, Vanderbilt University, 777 Preston Research Building, 2220 Pierce Ave, Nashville, TN 37232-6307, USA.
Gailani
David
D
D000818:Animals; D004195:Disease Models, Animal; D005164:Factor IX / Q000737:chemistry / Q000378:metabolism / Q000502:physiology*; D005173:Factor XI Deficiency / Q000378:metabolism / Q000473:pathology / Q000628:therapy; D015945:Factor XIa / Q000737:chemistry / Q000378:metabolism* / Q000502:physiology; D006801:Humans; D013927:Thrombosis / Q000473:pathology
D005164:Factor IX; D015945:Factor XIa